Current Treatment Landscape of AQP4-IgG+ NMOSD and Considerations on Relapse Rates

Michael Levy, MD, PhD, discusses how Aquaporin-4 IgG-seropositive neuromyelitis optica spectrum disorder (AQP4-IgG+ NMOSD) is a rare autoimmune condition affecting the central nervous system. Anti-CD20 therapies, particularly rituximab, have demonstrated efficacy in managing NMOSD, offering a valuable treatment option.:

Source: Neurology Read More